[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_f0915104-1dc1-4ccf-823e-e2d39a7c330d":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:f0915104-1dc1-4ccf-823e-e2d39a7c330d,\"}":37},{"code":4,"data":5,"meta":19},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":21,"manageAffiliations":22,"indexDatabases":23,"url":24,"thumbnailPath":19,"statistic":25,"gsStatistic":19,"type":36,"analyzePriority":19},"f0915104-1dc1-4ccf-823e-e2d39a7c330d","2024-04-11T06:19:06.873+00:00","2024-05-03T23:40:33.370+00:00",[],"CardioVasc",{"issn":12,"eissn":14,"title":16},{"VOID":13},"1618-3851",{"VOID":15},"1617-4933",{"EN":10},"PUBLISHER","PENDING",null,0,[],[],[],"https:\u002F\u002Flink.springer.com\u002Fjournal\u002F15027",{"impactFactor":20,"impactFactorByYear":26,"i10Index":20,"i10IndexLast5Year":20,"totalPublication":27,"totalPublicationByYear":28,"totalCitation":20,"totalCitationByYear":34,"totalCitationPerPublication":20,"totalCitationPerPublicationByYear":35,"hindexLast5Year":20,"hindex":20},{},24,{"2014":29,"2015":30,"2016":31,"2017":32,"2018":29,"2019":29,"2022":33,"2023":29},3,2,4,1,5,{},{},"JOURNAL",{"meta":38,"data":40},{"total":39},"2191",[41,87,144,194,250,284,338,384,419,465],{"id":42,"createTime":43,"updateTime":43,"relativeEntities":44,"slug":19,"properties":45,"entityType":52,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":53,"fullTextUrl":19,"authors":54,"publicationType":63,"publisherRelationship":64,"citationCount":19,"citationInfo":19,"publishDate":84,"publishYear":85,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":86},"91ef5317-4ec3-4d9c-b669-c1e0101d3c73","2024-01-04T23:59:58.935+00:00",[],{"abstract":46,"title":48,"doi":50},{"EN":47},"Hatten die letzten Jahre den Eindruck vermittelt, dass die Herzchirurgen hauptsächlich damit beschäftigt sind, das dynamische Vordringen der interventionellen Kardiologie „kritisch zu begleiten“, so präsentierten sie sich auf ihrer Jahrestagung als konsensfähig, selbstbewusst und innovativ. Bestes Beispiel: die minimalinvasiven Operationskonzepte — „where the future is“, wie der scheidende DGTHG-Präsident Prof. Jochen Cremer aus Kiel stolz proklamierte.",{"EN":49},"Trend zu schonenderen Operations-Methoden",{"VOID":51},"10.1007\u002Fs15027-015-0590-3","PUBLICATION","https:\u002F\u002Fwww.springermedizin.de\u002Ftrend-zu-schonenderen-operations-methoden\u002F9321600?fulltextView=true&doi=10.1007%2Fs15027-015-0590-3",[55],{"id":56,"sortIndex":20,"researcher":19,"roles":57,"affiliations":59,"properties":60},"2a9973bd-b869-48e2-92bc-6a658d86e312",[58],"AUTHOR",[],{"title":61},{"VI":62},"Jochen Aumiller","ARTICLE",{"url":53,"publisher":65,"properties":79},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":66,"slug":10,"properties":67,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":71,"manageAffiliations":72,"indexDatabases":73,"url":24,"thumbnailPath":19,"statistic":74,"gsStatistic":19,"type":36,"analyzePriority":19},[],{"issn":68,"eissn":69,"title":70},{"VOID":13},{"VOID":15},{"EN":10},[],[],[],{"impactFactor":20,"impactFactorByYear":75,"i10Index":20,"i10IndexLast5Year":20,"totalPublication":27,"totalPublicationByYear":76,"totalCitation":20,"totalCitationByYear":77,"totalCitationPerPublication":20,"totalCitationPerPublicationByYear":78,"hindexLast5Year":20,"hindex":20},{},{"2014":29,"2015":30,"2016":31,"2017":32,"2018":29,"2019":29,"2022":33,"2023":29},{},{},{"volume":80,"pages":82},{"VOID":81},"15",{"VOID":83},"16-18","2015-03-20",2015,false,{"id":88,"createTime":89,"updateTime":90,"relativeEntities":91,"slug":92,"properties":93,"entityType":52,"verifyStatus":102,"verifyTime":90,"verifyNote":103,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":32,"primaryUrl":104,"fullTextUrl":19,"authors":105,"publicationType":63,"publisherRelationship":122,"citationCount":19,"citationInfo":19,"publishDate":142,"publishYear":143,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":86},"5ca922ec-3636-440c-a805-2c00d69ced37","2024-01-30T16:01:56.765+00:00","2025-02-04T23:58:35.279+00:00",[],"Postprandiale-Hypotonie-als-Pr%C3%A4diktor-f%C3%BCr-die-Prognose-",{"references":94,"abstract":96,"title":98,"doi":100},{"VOID":95},"Zanasi A et al. Meal-induced blood pressure variation and cardiovascular mortality in ambulatory hypertensive elderly patients: preliminary results. J Hypertens 2012;30:2125–2132",{"EN":97},"Die postprandiale Hypotonie tritt besonders bei älteren Menschen nicht selten auf und hat schon auf mancher Jubiläumsfeier durch Synkope und Notarzteinsatz für jähe Bestürzung gesorgt. Einer aktuellen Studie zufolge haben solche Ereignisse eine Bedeutung hinsichtlich der kardiovaskulären Prognose.",{"EN":99},"Postprandiale Hypotonie als Prädiktor für die Prognose?",{"VOID":101},"10.1007\u002Fs15027-013-0030-6","VERIFIED","Auto Verify","https:\u002F\u002Fwww.springermedizin.de\u002Fpostprandiale-hypotonie-als-praediktor-fuer-die-prognose\u002F9320490?fulltextView=true&doi=10.1007%2Fs15027-013-0030-6",[106],{"id":107,"sortIndex":20,"researcher":19,"roles":108,"affiliations":109,"properties":119},"e9fa08d0-cede-490b-8f7b-140a34387c67",[58],[110],{"id":19,"sortIndex":20,"affiliation":111,"properties":19},{"id":112,"createTime":113,"updateTime":113,"relativeEntities":114,"slug":19,"properties":115,"entityType":118,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"12ecd7ec-fdda-4192-b766-3f72551ecc84","2024-02-11T04:15:32.291+00:00",[],{"title":116},{"VI":117},"Medizinische Klinik IV, Charité, Berlin, Deutschland","AFFILIATION",{"title":120},{"VI":121},"Walter Zidek",{"url":104,"publisher":123,"properties":137},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":124,"slug":10,"properties":125,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":129,"manageAffiliations":130,"indexDatabases":131,"url":24,"thumbnailPath":19,"statistic":132,"gsStatistic":19,"type":36,"analyzePriority":19},[],{"issn":126,"eissn":127,"title":128},{"VOID":13},{"VOID":15},{"EN":10},[],[],[],{"impactFactor":20,"impactFactorByYear":133,"i10Index":20,"i10IndexLast5Year":20,"totalPublication":27,"totalPublicationByYear":134,"totalCitation":20,"totalCitationByYear":135,"totalCitationPerPublication":20,"totalCitationPerPublicationByYear":136,"hindexLast5Year":20,"hindex":20},{},{"2014":29,"2015":30,"2016":31,"2017":32,"2018":29,"2019":29,"2022":33,"2023":29},{},{},{"volume":138,"pages":140},{"VOID":139},"13",{"VOID":141},"56-56","2013-02-21",2013,{"id":145,"createTime":146,"updateTime":147,"relativeEntities":148,"slug":149,"properties":150,"entityType":52,"verifyStatus":102,"verifyTime":147,"verifyNote":103,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":155,"fullTextUrl":19,"authors":156,"publicationType":63,"publisherRelationship":172,"citationCount":19,"citationInfo":19,"publishDate":192,"publishYear":193,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":86},"db9072bb-2578-44c5-9fc2-57ea117ae220","2024-02-07T12:46:48.519+00:00","2025-01-21T23:58:24.738+00:00",[],"Triglyzerid-Senkung-mit-Fibrat-ohne-klinischen-Nutzen-in-gro%C3%9Fer-Studie",{"title":151,"doi":153},{"EN":152},"Triglyzerid-Senkung mit Fibrat ohne klinischen Nutzen in großer Studie",{"VOID":154},"10.1007\u002Fs15027-022-2949-6","https:\u002F\u002Fwww.springermedizin.de\u002Ffibrate\u002Fnikotinsaeure\u002Ftriglyzerid-senkung-mit-fibrat-ohne-klinischen-nutzen-in-grosser\u002F23830732?fulltextView=true&doi=10.1007%2Fs15027-022-2949-6",[157],{"id":158,"sortIndex":20,"researcher":19,"roles":159,"affiliations":160,"properties":169},"20662398-916d-4be1-ba58-bc6d38b69a1f",[58],[161],{"id":19,"sortIndex":20,"affiliation":162,"properties":19},{"id":163,"createTime":164,"updateTime":164,"relativeEntities":165,"slug":19,"properties":166,"entityType":118,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"58894c04-1c20-4d9e-9c7c-ccef1633cbe5","2024-01-04T09:50:12.001+00:00",[],{"title":167},{"VI":168},"Springer Medizin, Neu-Isenburg, Deutschland",{"title":170},{"VI":171},"Peter Overbeck",{"url":155,"publisher":173,"properties":187},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":174,"slug":10,"properties":175,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":179,"manageAffiliations":180,"indexDatabases":181,"url":24,"thumbnailPath":19,"statistic":182,"gsStatistic":19,"type":36,"analyzePriority":19},[],{"issn":176,"eissn":177,"title":178},{"VOID":13},{"VOID":15},{"EN":10},[],[],[],{"impactFactor":20,"impactFactorByYear":183,"i10Index":20,"i10IndexLast5Year":20,"totalPublication":27,"totalPublicationByYear":184,"totalCitation":20,"totalCitationByYear":185,"totalCitationPerPublication":20,"totalCitationPerPublicationByYear":186,"hindexLast5Year":20,"hindex":20},{},{"2014":29,"2015":30,"2016":31,"2017":32,"2018":29,"2019":29,"2022":33,"2023":29},{},{},{"volume":188,"pages":190},{"VOID":189},"22",{"VOID":191},"8-9","2022-12-15",2022,{"id":195,"createTime":196,"updateTime":197,"relativeEntities":198,"slug":199,"properties":200,"entityType":52,"verifyStatus":18,"verifyTime":197,"verifyNote":209,"syncStatus":18,"languages":210,"translateLanguages":19,"viewCount":20,"primaryUrl":212,"fullTextUrl":19,"authors":213,"publicationType":63,"publisherRelationship":223,"citationCount":20,"citationInfo":245,"publishDate":247,"publishYear":248,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":249,"isForceReanalyzing":86},"f4934295-adae-4ca7-9c1e-4ca506297ea0","2024-04-17T20:17:03.780+00:00","2025-01-15T23:58:02.731+00:00",[],"CKD-Patienten-haben-h%C3%B6heres-koronares-Risiko-als-Diabetiker",{"keywords":201,"openalex":202,"abstract":204,"title":205,"doi":207},{},{"VOID":203},"W4206360551",{},{"DE":206},"CKD-Patienten haben höheres koronares Risiko als Diabetiker",{"VOID":208},"10.1007\u002Fs15027-012-0203-3","Author affiliation is blank",[211],"DE","https:\u002F\u002Fwww.springermedizin.de\u002Fdoi\u002F10.1007\u002Fs15027-012-0203-3",[214],{"id":215,"sortIndex":20,"researcher":19,"roles":216,"affiliations":217,"properties":218},"3529a622-9d54-42d3-aa62-3ba589f451e3",[],[],{"openalex":219,"title":221},{"VOID":220},"A5061852278",{"EN":222},"J.A.",{"url":19,"publisher":224,"properties":238},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":225,"slug":10,"properties":226,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":230,"manageAffiliations":231,"indexDatabases":232,"url":24,"thumbnailPath":19,"statistic":233,"gsStatistic":19,"type":36,"analyzePriority":19},[],{"issn":227,"eissn":228,"title":229},{"VOID":13},{"VOID":15},{"EN":10},[],[],[],{"impactFactor":20,"impactFactorByYear":234,"i10Index":20,"i10IndexLast5Year":20,"totalPublication":27,"totalPublicationByYear":235,"totalCitation":20,"totalCitationByYear":236,"totalCitationPerPublication":20,"totalCitationPerPublicationByYear":237,"hindexLast5Year":20,"hindex":20},{},{"2014":29,"2015":30,"2016":31,"2017":32,"2018":29,"2019":29,"2022":33,"2023":29},{},{},{"volume":239,"pages":241,"issue":243},{"VOID":240},"12",{"VOID":242},"26-26",{"VOID":244},"4",{"total":20,"publishYear":19,"statisticByYear":246},{},"2012-09-01",2012,[],{"id":251,"createTime":252,"updateTime":253,"relativeEntities":254,"slug":255,"properties":256,"entityType":52,"verifyStatus":18,"verifyTime":253,"verifyNote":261,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":262,"fullTextUrl":19,"authors":263,"publicationType":63,"publisherRelationship":264,"citationCount":19,"citationInfo":19,"publishDate":283,"publishYear":143,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":86},"357ba99d-c9ab-400d-b548-d3e52dadfa57","2024-01-19T02:30:52.728+00:00","2025-02-26T23:57:41.271+00:00",[],"Schlafapnoe-Risikofaktor-vor-und-nach-Schlaganfall",{"title":257,"doi":259},{"EN":258},"Schlafapnoe: Risikofaktor vor und nach Schlaganfall",{"VOID":260},"10.1007\u002Fs15027-013-0192-x","Author title is blank","https:\u002F\u002Fwww.springermedizin.de\u002Fschlafapnoe-risikofaktor-vor-und-nach-schlaganfall\u002F9320796?fulltextView=true&doi=10.1007%2Fs15027-013-0192-x",[],{"url":262,"publisher":265,"properties":279},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":266,"slug":10,"properties":267,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":271,"manageAffiliations":272,"indexDatabases":273,"url":24,"thumbnailPath":19,"statistic":274,"gsStatistic":19,"type":36,"analyzePriority":19},[],{"issn":268,"eissn":269,"title":270},{"VOID":13},{"VOID":15},{"EN":10},[],[],[],{"impactFactor":20,"impactFactorByYear":275,"i10Index":20,"i10IndexLast5Year":20,"totalPublication":27,"totalPublicationByYear":276,"totalCitation":20,"totalCitationByYear":277,"totalCitationPerPublication":20,"totalCitationPerPublicationByYear":278,"hindexLast5Year":20,"hindex":20},{},{"2014":29,"2015":30,"2016":31,"2017":32,"2018":29,"2019":29,"2022":33,"2023":29},{},{},{"volume":280,"pages":281},{"VOID":139},{"VOID":282},"68-68","2013-09-21",{"id":285,"createTime":286,"updateTime":287,"relativeEntities":288,"slug":289,"properties":290,"entityType":52,"verifyStatus":102,"verifyTime":287,"verifyNote":103,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":299,"fullTextUrl":19,"authors":300,"publicationType":63,"publisherRelationship":316,"citationCount":19,"citationInfo":19,"publishDate":336,"publishYear":337,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":86},"06bd76f1-2cce-4f69-90c7-5704cb17a6ac","2024-02-10T08:11:37.452+00:00","2024-12-27T23:57:08.939+00:00",[],"Schmerzen-nach-Schlaganfall",{"references":291,"abstract":293,"title":295,"doi":297},{"VOID":292},"Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and Molecular Mechanisms of Pain. Cell. 2009;139(2):267–84\nElliot KJ. Taxonomy and mechanisms of neuropathic pain. Semin Neurol. 1994;14:195–205\nO’Donnell MJ, Diener HC, Sacco RL et al. Chronic Pain Syndromes After Ischemic Stroke - PRoFESS Trial. Stroke. 2013;44:1238–43\nDejerine J, Roussy G. Le syndrome thalamique. Rev Neurol. 1906;12:521–32\nMulla SM, Wang L, Khokhar R et al. Management of Central Poststroke Pain Systematic Review of Randomized Controlled Trials. Stroke. 2015;46:2853–60\nSegatore M. Understanding central post-stroke pain. J Neurosci Nurs. 1996;28(1):28–35\nHead H, Holmes G. Sensory disturbances from cerebral lesions. Brain. 1911;34:102–254\nBoivie J, Leijon G, Johansson I. Central post-stroke pain—a study of the mechanisms through analyses of the sensory abnormalities. Pain. 1989;37(2):173–85\nMisra UK, Kalita J, Kumar B. A Study of Clinical, Magnetic Resonance Imaging, and Somatosensory-Evoked Potential in Central Post-Stroke Pain. J Pain. 2008;9(12):1116–22\nSeghier ML, Lazeyras F, Vuilleumier P et al. Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging in a Case of Central Poststroke Pain. J Pain. 2005;6(3):208–12\nKumar B, Kalita J, Kumar G, Misra UK. Central Poststroke Pain: A Review of Pathophysiology and Treatment. Anesth Analg. 2009;108(5):1645–57\nAndersen G, Vestergaard K, Ingeman-Nielsen M, Jensen TS. Incidence of central post-stroke pain. Pain. 1995;61(2):187–93\nVestergaard K, Nieksen J, Andersen G, Jensen TS. Sensory abnormalities in consecutive, unselected patients with central post-stroke pain. Pain. 1995;61(2):177–86\nLeijon G, Boivie J. Central post-stroke pain: a controlled trial of amitriptyline and carbamazepine. Pain. 1989;36:27–36\nLampl C, Yazdi K, Röper C. Amitriptyline in the prophylaxis of central poststroke pain. Stroke. 2003;33:3030–2\nShimodozono M, Kawahira K, Kamishita T, Tanaka N. Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine. Int J Neuroscience. 2002;112:1173–81\nCastel A, Vachon P. Gabapentin reverses central pain sensitization following a collagenase-induced intrathalamic hemorrhage in rats. J Pain Res. 2014;7:5–12\nHesami O, Gharagozli K, Beladimoghadam N et al. The Efficacy of Gabapentin in Patients with Central Post-stroke Pain. Iran J Pharm Res. 2015;14:95–101\nDrahn S. Medikamentös-toxische Enzephalopathie. CardioVasc. 2016;16(5):45–50\nVestergaard K, Andersen G, Gottrup H et al. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology. 2001;56:184–90\nBainton T, Fox M, Bowsher D, Wells C. A double-blind trial of naloxone in central post-stroke pain. Pain. 1992; 48(2):159–62\nChen CC, Chuang YF, Huang AC et al. The antalgic effects of non-invasive physical modalities on central post-stroke pain: a systematic review. J Phys Ther Sci. 2016;28(4):1368–73\nCho SY, Park JY, Jung WS et al. Bee venom acupuncture point injection for central post stroke pain: a preliminary single-blind randomized controlled trial. Complement Ther Med. 2013;21(3):155–7\nJiang Z, Li C, Li Y. Treatment of postapoplectic thalamic spontaneous pain by electroacupuncture at huatuojiaji points. J Tradit Chin Med. 1999;19:195–9\nO'Brien AT, Amorim R, Rushmore RJ et al. Motor Cortex Neurostimulation Technologies for Chronic Post-stroke Pain: Implications of Tissue Damage on Stimulation Currents. Front Hum Neurosci. 2016;10:545\nBittar RG, Kar-Purkayastha I, Owen SL et al. Deep brain stimulation for pain relief: a meta-analysis. J Clin Neurosci. 2005;12(5):515–9\nOwen SL, Green AL, Stein JF, Aziz TZ. Deep brain stimulation for the alleviation of post-stroke neuropathic pain. Pain. 2006;120(1-2):202–6\nRasche D, Rinaldi PC, Young RF, Tronnier VM. Deep brain stimulation for the treatment of various chronic pain syndromes. Neurosurg Focus. 2006;21(6):E8",{"EN":294},"Die Entwicklung eines chronischen Schmerzsyndroms nach ischämischem oder hämorrhagischem Schlaganfall ist nicht selten. Dachte man früher bei zentralen Schmerzen noch ausschließlich an thalamische Läsionen, weiß man heute, dass auf allen Ebenen der Neuroachse die Schmerzwahrnehmung beeinflusst werden kann. Diagnostik und eine effektive Therapie sind für die Lebensqualität der betroffenen Patienten entscheidend.",{"EN":296},"Schmerzen nach Schlaganfall",{"VOID":298},"10.1007\u002Fs15027-017-1053-9","https:\u002F\u002Fwww.springermedizin.de\u002Fdoi\u002F10.1007\u002Fs15027-017-1053-9",[301],{"id":302,"sortIndex":20,"researcher":19,"roles":303,"affiliations":304,"properties":313},"f6bab71a-cf86-4e99-9a1b-a8c43f7218ce",[58],[305],{"id":19,"sortIndex":20,"affiliation":306,"properties":19},{"id":307,"createTime":308,"updateTime":308,"relativeEntities":309,"slug":19,"properties":310,"entityType":118,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"88176314-d2ff-450a-b6c2-d9a1d48a11c4","2023-12-31T05:13:29.430+00:00",[],{"title":311},{"VI":312},"Bundeswehrkrankenhaus Berlin, Berlin, Deutschland",{"title":314},{"VI":315},"Steven Drahn",{"url":299,"publisher":317,"properties":331},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":318,"slug":10,"properties":319,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":323,"manageAffiliations":324,"indexDatabases":325,"url":24,"thumbnailPath":19,"statistic":326,"gsStatistic":19,"type":36,"analyzePriority":19},[],{"issn":320,"eissn":321,"title":322},{"VOID":13},{"VOID":15},{"EN":10},[],[],[],{"impactFactor":20,"impactFactorByYear":327,"i10Index":20,"i10IndexLast5Year":20,"totalPublication":27,"totalPublicationByYear":328,"totalCitation":20,"totalCitationByYear":329,"totalCitationPerPublication":20,"totalCitationPerPublicationByYear":330,"hindexLast5Year":20,"hindex":20},{},{"2014":29,"2015":30,"2016":31,"2017":32,"2018":29,"2019":29,"2022":33,"2023":29},{},{},{"volume":332,"pages":334},{"VOID":333},"17",{"VOID":335},"34-40","2017-10-30",2017,{"id":339,"createTime":340,"updateTime":341,"relativeEntities":342,"slug":343,"properties":344,"entityType":52,"verifyStatus":18,"verifyTime":341,"verifyNote":209,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":353,"fullTextUrl":19,"authors":354,"publicationType":63,"publisherRelationship":362,"citationCount":19,"citationInfo":19,"publishDate":382,"publishYear":383,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":86},"bba59f7c-c69b-49df-9cbf-57db231d39d6","2023-12-12T07:55:34.675+00:00","2025-01-16T23:56:27.775+00:00",[],"Herzinsuffizienz-Wann-Betablocker-das-Leben-nicht-verl%C3%A4ngern",{"references":345,"abstract":347,"title":349,"doi":351},{"VOID":346},"Cardio Update 2018, 2.–3. März 2018 in Berlin",{"EN":348},"Jeder Patient mit chronischer Herzinsuffizienz sollte einen Betablocker bekommen — aber nur, wenn sein Herz im Sinusrhythmus schlägt und seine Ejektionsfraktion unter 50 % beträgt. Woher man das weiß und was es sonst Neues gibt, erläuterte Prof. Michael Böhm, Universitätsklinikum Homburg\u002FSaar.",{"EN":350},"Herzinsuffizienz: Wann Betablocker das Leben nicht verlängern",{"VOID":352},"10.1007\u002Fs15027-018-1361-8","https:\u002F\u002Fwww.springermedizin.de\u002Fdoi\u002F10.1007\u002Fs15027-018-1361-8",[355],{"id":356,"sortIndex":20,"researcher":19,"roles":357,"affiliations":358,"properties":359},"614c5e83-bd8e-48f1-920d-de1309021227",[58],[],{"title":360},{"VI":361},"Manuela Arand",{"url":353,"publisher":363,"properties":377},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":364,"slug":10,"properties":365,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":369,"manageAffiliations":370,"indexDatabases":371,"url":24,"thumbnailPath":19,"statistic":372,"gsStatistic":19,"type":36,"analyzePriority":19},[],{"issn":366,"eissn":367,"title":368},{"VOID":13},{"VOID":15},{"EN":10},[],[],[],{"impactFactor":20,"impactFactorByYear":373,"i10Index":20,"i10IndexLast5Year":20,"totalPublication":27,"totalPublicationByYear":374,"totalCitation":20,"totalCitationByYear":375,"totalCitationPerPublication":20,"totalCitationPerPublicationByYear":376,"hindexLast5Year":20,"hindex":20},{},{"2014":29,"2015":30,"2016":31,"2017":32,"2018":29,"2019":29,"2022":33,"2023":29},{},{},{"volume":378,"pages":380},{"VOID":379},"18",{"VOID":381},"19-20","2018-05-24",2018,{"id":385,"createTime":386,"updateTime":387,"relativeEntities":388,"slug":389,"properties":390,"entityType":52,"verifyStatus":18,"verifyTime":387,"verifyNote":261,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":395,"fullTextUrl":19,"authors":396,"publicationType":63,"publisherRelationship":397,"citationCount":19,"citationInfo":19,"publishDate":417,"publishYear":418,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":86},"8aedb37d-1074-49a4-a9d5-ab087d43a2ec","2024-02-11T17:54:15.082+00:00","2025-02-07T23:56:05.172+00:00",[],"Was-gibt-es-Neues-aus-der-Lipidforschung-",{"title":391,"doi":393},{"EN":392},"Was gibt es Neues aus der Lipidforschung?",{"VOID":394},"10.1007\u002FBF03358909","https:\u002F\u002Fwww.springermedizin.de\u002Fwas-gibt-es-neues-aus-der-lipidforschung\u002F10311156?fulltextView=true&doi=10.1007%2FBF03358909",[],{"url":395,"publisher":398,"properties":412},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":399,"slug":10,"properties":400,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":404,"manageAffiliations":405,"indexDatabases":406,"url":24,"thumbnailPath":19,"statistic":407,"gsStatistic":19,"type":36,"analyzePriority":19},[],{"issn":401,"eissn":402,"title":403},{"VOID":13},{"VOID":15},{"EN":10},[],[],[],{"impactFactor":20,"impactFactorByYear":408,"i10Index":20,"i10IndexLast5Year":20,"totalPublication":27,"totalPublicationByYear":409,"totalCitation":20,"totalCitationByYear":410,"totalCitationPerPublication":20,"totalCitationPerPublicationByYear":411,"hindexLast5Year":20,"hindex":20},{},{"2014":29,"2015":30,"2016":31,"2017":32,"2018":29,"2019":29,"2022":33,"2023":29},{},{},{"volume":413,"pages":415},{"VOID":414},"11",{"VOID":416},"63-63","2016-06-25",2016,{"id":420,"createTime":421,"updateTime":422,"relativeEntities":423,"slug":424,"properties":425,"entityType":52,"verifyStatus":18,"verifyTime":434,"verifyNote":209,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":435,"fullTextUrl":19,"authors":436,"publicationType":63,"publisherRelationship":443,"citationCount":19,"citationInfo":19,"publishDate":463,"publishYear":464,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":86},"a47636ba-950c-458e-8c88-a58cc091121e","2024-02-20T03:24:07.536+00:00","2024-12-20T23:55:29.035+00:00",[],"Erster-oraler-GLP-1-Agonist-zeigt-gutes-kardiovaskul%C3%A4res-Sicherheitsprofil",{"references":426,"abstract":428,"title":430,"doi":432},{"VOID":427},"Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabete. N Engl J Med. 2019, https:\u002F\u002Fdoi.org\u002F10.1056\u002FNEJMoa1901118",{"EN":429},"Als erster oral applizierbarer GLP-1-Rezeptoragonist hat Semaglutid in der randomisierten PIONEER-6-Studie in puncto kardiovaskuläre Sicherheit die Erwartungen voll erfüllt.",{"EN":431},"Erster oraler GLP-1-Agonist zeigt gutes kardiovaskuläres Sicherheitsprofil",{"VOID":433},"10.1007\u002Fs15027-019-1587-0","2024-12-20T23:55:29.034+00:00","https:\u002F\u002Fwww.springermedizin.de\u002Ftyp-2-diabetes\u002Fapoplex\u002Ferster-oraler-glp-1-agonist-zeigt-gutes-kardiovaskulaeres-sicher\u002F17208234?fulltextView=true&doi=10.1007%2Fs15027-019-1587-0",[437],{"id":438,"sortIndex":20,"researcher":19,"roles":439,"affiliations":440,"properties":441},"c5114f3c-d162-4183-88f2-41fe80134262",[58],[],{"title":442},{"VI":171},{"url":435,"publisher":444,"properties":458},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":445,"slug":10,"properties":446,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":450,"manageAffiliations":451,"indexDatabases":452,"url":24,"thumbnailPath":19,"statistic":453,"gsStatistic":19,"type":36,"analyzePriority":19},[],{"issn":447,"eissn":448,"title":449},{"VOID":13},{"VOID":15},{"EN":10},[],[],[],{"impactFactor":20,"impactFactorByYear":454,"i10Index":20,"i10IndexLast5Year":20,"totalPublication":27,"totalPublicationByYear":455,"totalCitation":20,"totalCitationByYear":456,"totalCitationPerPublication":20,"totalCitationPerPublicationByYear":457,"hindexLast5Year":20,"hindex":20},{},{"2014":29,"2015":30,"2016":31,"2017":32,"2018":29,"2019":29,"2022":33,"2023":29},{},{},{"volume":459,"pages":461},{"VOID":460},"19",{"VOID":462},"15-16","2019-09-25",2019,{"id":466,"createTime":467,"updateTime":468,"relativeEntities":469,"slug":470,"properties":471,"entityType":52,"verifyStatus":18,"verifyTime":468,"verifyNote":209,"syncStatus":18,"languages":482,"translateLanguages":19,"viewCount":20,"primaryUrl":483,"fullTextUrl":19,"authors":484,"publicationType":63,"publisherRelationship":530,"citationCount":20,"citationInfo":545,"publishDate":547,"publishYear":418,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":548,"isForceReanalyzing":86},"1e19c2dd-b5e2-4652-81eb-db0ea5c84286","2024-04-15T20:39:21.284+00:00","2024-09-27T23:54:16.101+00:00",[],"SGLT2-Antagonisten-ein-Medikament-gegen-Diabetes-und-Bluthochdruck-",{"mag":472,"keywords":474,"openalex":475,"abstract":477,"title":478,"doi":480},{"VOID":473},"2509537013",{},{"VOID":476},"W2509537013",{},{"DE":479},"SGLT2-Antagonisten – ein Medikament gegen Diabetes und Bluthochdruck?",{"VOID":481},"10.1007\u002Fs15027-016-0819-9",[211],"https:\u002F\u002Fwww.springermedizin.de\u002Fdoi\u002F10.1007\u002Fs15027-016-0819-9",[485,503,521],{"id":486,"sortIndex":20,"researcher":19,"roles":487,"affiliations":488,"properties":498},"b4076231-860a-457f-8a02-4c8a7e0add2b",[],[489],{"id":19,"sortIndex":20,"affiliation":490,"properties":19},{"id":491,"createTime":492,"updateTime":492,"relativeEntities":493,"slug":494,"properties":495,"entityType":118,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"3b5f0787-4495-40d3-b983-a2d91b2bc239","2024-04-15T20:39:21.295+00:00",[],"Charit%C3%A9-Universit%C3%A4tsmedizin-Berlin-Campus-Benjamin-Franklin-Klinik-f%C3%BCr-Nephrologie-und-Tranplantationsmedizin-Hypertoniezentrum-Berlin-Deutschland",{"title":496},{"EN":497},"Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Nephrologie und Tranplantationsmedizin, Hypertoniezentrum, Berlin, Deutschland",{"openalex":499,"title":501},{"VOID":500},"A5072483867",{"EN":502},"Alexander Reshetnik",{"id":504,"sortIndex":30,"researcher":19,"roles":505,"affiliations":506,"properties":516},"b9ee4dd2-d00d-4198-9e11-17c7337b1b93",[],[507],{"id":19,"sortIndex":20,"affiliation":508,"properties":19},{"id":509,"createTime":510,"updateTime":510,"relativeEntities":511,"slug":512,"properties":513,"entityType":118,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"3fb014df-e9ff-4f15-ba09-5239b2a6aab2","2024-04-15T20:39:21.313+00:00",[],"Klinik-f%C3%BCr-Nephrologie-und-Tranplantationsmedizin-Hypertoniezentrum",{"title":514},{"EN":515},"Klinik für Nephrologie und Tranplantationsmedizin, Hypertoniezentrum",{"openalex":517,"title":519},{"VOID":518},"A5015274001",{"EN":520},"Markus van der Giet",{"id":522,"sortIndex":32,"researcher":19,"roles":523,"affiliations":524,"properties":525},"fa9f6b22-a5e2-4665-a8bf-1219ecb3e9dc",[],[],{"openalex":526,"title":528},{"VOID":527},"A5082551560",{"EN":529},"Christopher Gohlisch",{"url":19,"publisher":531,"properties":19},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":532,"slug":10,"properties":533,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":537,"manageAffiliations":538,"indexDatabases":539,"url":24,"thumbnailPath":19,"statistic":540,"gsStatistic":19,"type":36,"analyzePriority":19},[],{"issn":534,"eissn":535,"title":536},{"VOID":13},{"VOID":15},{"EN":10},[],[],[],{"impactFactor":20,"impactFactorByYear":541,"i10Index":20,"i10IndexLast5Year":20,"totalPublication":27,"totalPublicationByYear":542,"totalCitation":20,"totalCitationByYear":543,"totalCitationPerPublication":20,"totalCitationPerPublicationByYear":544,"hindexLast5Year":20,"hindex":20},{},{"2014":29,"2015":30,"2016":31,"2017":32,"2018":29,"2019":29,"2022":33,"2023":29},{},{},{"total":20,"publishYear":19,"statisticByYear":546},{},"2016-03-01",[549,553,557,561,565,568,572,576,579,583,587,590,594,598,602,606,610],{"id":19,"text":550,"url":19,"identifiers":551},"Sowers JR, Epstein M and Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053–9",{"doi":552},"10.1161\u002F01.HYP.37.4.1053",{"id":19,"text":554,"url":19,"identifiers":555},"Rahmouni K, Correia ML, Haynes WG and Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45:9–14",{"doi":556},"10.1161\u002F01.HYP.0000151325.83008.b4",{"id":19,"text":558,"url":19,"identifiers":559},"Ehrenkranz JR, Lewis NG, Kahn CR and Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21:31–8",{"doi":560},"10.1002\u002Fdmrr.532",{"id":19,"text":562,"url":19,"identifiers":563},"Baker WL, Smyth LR, Riche DM et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262–75.e9",{"doi":564},"10.1016\u002Fj.jash.2014.01.007",{"id":19,"text":566,"url":19,"identifiers":567},"Solini A. Extra-glycaemic properties of empagliflozin. Diabetes Metab Res Rev. 2015. doi: 10.1002\u002Fdmrr.2666",{},{"id":19,"text":569,"url":19,"identifiers":570},"Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74",{"doi":571},"10.7326\u002F0003-4819-159-4-201308200-00007",{"id":19,"text":573,"url":19,"identifiers":574},"List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–7",{"doi":575},"10.2337\u002Fdc08-1863",{"id":19,"text":577,"url":19,"identifiers":578},"Kim GRM, Andersen KR, Zeller C et al. Effect of empagliflozin compared with glimepiride as add-on to metformin for 2 years on the amount and distribution of body fat in patients with type 2 diabetes. Diabetologia 2014;75(Suppl. 1):330, 818.",{},{"id":19,"text":580,"url":19,"identifiers":581},"Ferrannini G, Hach T, Crowe S et al. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38:1730–5",{"doi":582},"10.2337\u002Fdc15-0355",{"id":19,"text":584,"url":19,"identifiers":585},"Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–97",{"doi":586},"10.1161\u002FCIRCULATIONAHA.113.005081",{"id":19,"text":588,"url":19,"identifiers":589},"Fu YGM, Mayoux E, Masuda T, Vallon V. SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration. Diabetes 2014;63(Suppl. 1):512–P",{},{"id":19,"text":591,"url":19,"identifiers":592},"Layton AT, Vallon V, Edwards A. Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. American journal of physiology. Ren Physiol. 2015;308:F1343–57",{"doi":593},"10.1152\u002Fajprenal.00007.2015",{"id":19,"text":595,"url":19,"identifiers":596},"Bailey CJ, Gross JL, Hennicken D et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC med. 2013;11:43",{"doi":597},"10.1186\u002F1741-7015-11-43",{"id":19,"text":599,"url":19,"identifiers":600},"Davies MJ, Trujillo A, Vijapurkar U et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:426–9",{"doi":601},"10.1111\u002Fdom.12439",{"id":19,"text":603,"url":19,"identifiers":604},"Ferrannini E, Berk A, Hantel S et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015–21",{"doi":605},"10.2337\u002Fdc13-0663",{"id":19,"text":607,"url":19,"identifiers":608},"Feig DI. The role of uric acid in the pathogenesis of hypertension in the young. J Clin Hypertens. 2012;14:346–52",{"doi":609},"10.1111\u002Fj.1751-7176.2012.00662.x",{"id":19,"text":611,"url":19,"identifiers":612},"Soletsky B and Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60:1148–56",{"doi":613},"10.1161\u002FHYPERTENSIONAHA.112.196980"]